Andrea De Censi, MD, PhD, National Hospital E.O. Ospedali Galliera – S.C. Oncologia Medica, Genoa, Italy, provides an overview of the Phase III TAM-01 (NCT01357772) clinical trial investigating low-dose tamoxifen versus placebo in patients with breast intraepithelial neoplasia, which includes woman with invasive breast cancer and ductal carcinoma in situ (DCIS). A previous biomarker trial had demonstrated a lower dose of tamoxifen was non-inferior to the standard dose but associated with fewer side-effects, providing the rationale for this clinical trial. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

0 Comments

Up next

Autoplay

Low-Dose Aspirin Regimen Provides No Significant Health Benefits For Older Adults, Studies Find

1 Views . 08/29/25 Side Effects

Please note that if you are under 18, you won't be able to access this site.

Up next

TAM-01: low-dose tamoxifen in women with breast intraepithelial neoplasia

Up next

Language